Barlow R
Department of Pharmacology, University of Bristol, Medical School, University Walk, UK.
Trends Pharmacol Sci. 1990 Apr;11(4):148-50. doi: 10.1016/0165-6147(90)90065-G.
In the 1950s Pfeiffer observed that the relative potencies of the enantiomers (mirror-image isomers) of several drugs appeared to be related to the dose of the racemate used clinically. The difference was greatest with the most active compounds and he suggested reasons for what has become known as 'Pfeiffer's rule'. In this short article Dick Barlow points out that there is a corollary to the rule - that the activity of the weaker enantiomer is determined by the activity of the more potent one - which is intuitively imporbable. With more examples and in a simpler situation, the picture is more complex and there are marked exceptions. The ideas behind Pfeiffer's rule overlook differences in molecular flexibility and there is a need for a revised model that takes entropy differences into account, particularly as recent developments in the elucidation of receptor structure are likely to revive interest in Pfeiffer's rule.
20世纪50年代, Pfeiffer观察到几种药物的对映体(镜像异构体)的相对效价似乎与临床上使用的外消旋体剂量有关。对于活性最强的化合物,这种差异最为显著,他提出了后来被称为“Pfeiffer规则”的原因。在这篇短文中,Dick Barlow指出该规则有一个推论——较弱对映体的活性由较强对映体的活性决定——这在直观上是不可能的。有了更多的例子且在更简单的情况下,情况更为复杂且存在明显的例外。Pfeiffer规则背后的观点忽略了分子柔韧性的差异,需要一个考虑熵差的修正模型,特别是因为受体结构阐明方面的最新进展可能会重新引发人们对Pfeiffer规则的兴趣。